Pfizer Says Elrexfio Shows Significant Benefit in RRMM
Pfizer reported a statistically significant benefit for Elrexfio in RRMM; median PFS has not yet been reached.
Related stories
Establishment Labs Reports Q3 Pretax Loss
M impact | EQUITY | Oct 29, 2026, 12:42 PM UTC
Western Superconducting Technologies Reports Q3 Net Loss of 83.0 Million Yuan
M impact | EQUITY | Oct 29, 2026, 12:42 PM UTC
Coal India Reports Q2 Consolidated Revenue of 441.79 Billion Rupees
M impact | EQUITY | Oct 29, 2026, 12:41 PM UTC
TCL Zhonghuan reports Q3 net loss of 1.4 billion yuan
M impact | EQUITY | Oct 29, 2026, 12:41 PM UTC
Air France Extends Flight Suspension to Riyadh and Dubai
M impact | EQUITY | Oct 29, 2026, 12:41 PM UTC
Wuxi Lead Intelligent Equipment Q3 Net Profit Up 41.74% Y/Y
M impact | EQUITY | Oct 29, 2026, 12:41 PM UTC